ESSA Pharma Inc. (EPIX)
NASDAQ: EPIX
· Real-Time Price · USD
1.73
-0.04 (-2.26%)
At close: May 02, 2025, 3:59 PM
1.72
-0.58%
After-hours: May 02, 2025, 04:08 PM EDT
-2.26% (1D)
| Bid | 1.71 |
| Market Cap | 76.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -31.11M |
| EPS (ttm) | -0.69 |
| PE Ratio (ttm) | -2.51 |
| Forward PE | -3.72 |
| Analyst | Hold |
| Ask | 1.91 |
| Volume | 186,959 |
| Avg. Volume (20D) | 194,346 |
| Open | 1.77 |
| Previous Close | 1.77 |
| Day's Range | 1.72 - 1.76 |
| 52-Week Range | 1.40 - 7.88 |
| Beta | 1.61 |
About EPIX
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and A...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 13, 2015
Employees 35
Stock Exchange NASDAQ
Ticker Symbol EPIX
Website https://www.essapharma.com
Analyst Forecast
According to 3 analyst ratings, the average rating for EPIX stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 15.61% from the latest price.
Stock Forecasts2 weeks ago
+8.59%
ESSA Pharma shares are trading higher after disclo...
Unlock content with
Pro Subscription
6 months ago
-73.08%
ESSA Pharma shares are trading lower after the company announced it terminated its Phase 2 study evaluating masofaniten combined with enzalutamide in patients with mCRPC
